The introduction of specific BCR-ABL inhibitors in chronic myelogenous leukemia therapy has entirely mutated the prognosis of this hematologic cancer from being a fatal disorder to becoming a chronic disease. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.